Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Clinical research trials and Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia. Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia clinical trial. Human subjects often obtain the finest healthcare possible for their Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.

Home > "D" Clinical Trials Conditions > Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia

Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia



Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia

For Condition: recurrent childhood acute lymphoblastic leukemia
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Children's Cancer Group
Synopsis: RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute lymphocytic leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try to detect changes in the genes of children who have been treated for relapsed acute lymphocytic leukemia.
Details: OBJECTIVES: I. Determine the incidence of p16/p15 homozygous deletions and p15 promoter hypermethylation in acute lymphocytic leukemia cells of children treated on protocol CCG-1941. II. Determine the prognostic importance of p16/p15 abnormalities in these children. III. Determine the presence or absence of p16/p15 abnormalities in the dominant clone at diagnosis if present at relapse in these patients. PROTOCOL OUTLINE: Frozen cells are obtained from samples collected on protocol CCG-1941. DNA is isolated and examined using Southern blot analysis to assay for deletions and promoter hypermethylation of p16 and/or p15. PROJECTED ACCRUAL: Approximately 100 samples will be obtained for this study.
Eligibility:
Study Type:
  Interventional, Diagnostic
Minimum Age/Maximum Age: /17 Years
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of acute lymphocytic leukemia and treated on protocol CCG-1941 - Material cryopreserved in the CCG cell bank --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: Children - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
StephenHunger,  Study Chair,  Children's Cancer Group

Long Beach Memorial Medical Center
Long Beach,  California,  90806
United States
 

Mount Sinai School of Medicine
New York City,  New York,  10029
United States
 

IWK Health Centre
Halifax,  Nova Scotia,  B3J 3G9
Canada
 

Herbert Irving Comprehensive Cancer Center
New York City,  New York,  10032
United States
 

University of Wisconsin Comprehensive Cancer Center
Madison,  Wisconsin,  53792-6164
United States
 

Children's Mercy Hospital
Kansas City,  Missouri,  64108
United States
 

British Columbia Children's Hospital
Vancouver,  British Columbia,  V6H 3V4
Canada
 

Children's Hospital of Pittsburgh
Pittsburgh,  Pennsylvania,  15213
United States
 

Memorial Sloan-Kettering Cancer Center
New York City,  New York,  10021
United States
 

Doernbecher Children's Hospital
Portland,  Oregon,  97201-3098
United States
 

Shands Hospital and Clinics, University of Florida
Gainesville,  Florida,  32610-100277
United States
 

Children's Hospital of Denver
Denver,  Colorado,  80218
United States
 

Veterans Affairs Medical Center - Fargo
Fargo,  North Dakota,  58102
United States
 

Mayo Clinic Cancer Center
Rochester,  Minnesota,  55905
United States
 

University of Chicago Cancer Research Center
Chicago,  Illinois,  60637-1470
United States
 

Indiana University Cancer Center
Indianapolis,  Indiana,  46202-5289
United States
 

University of Texas - MD Anderson Cancer Center
Houston,  Texas,  77030-4009
United States
 

CCOP - Merit Care Hospital
Fargo,  North Dakota,  58122
United States
 

CCOP - Kalamazoo
Kalamazoo,  Michigan,  49007-3731
United States
 

Children's Hospital Los Angeles
Los Angeles,  California,  90027-0700
United States
 

Children's Hospital of Columbus
Columbus,  Ohio,  43205-2696
United States
 

University of Nebraska Medical Center
Omaha,  Nebraska,  68198-3330
United States
 

Saint Peter's University Hospital
New Brunswick,  New Jersey,  08901-1780
United States
 

Vanderbilt-Ingram Cancer Center
Nashville,  Tennessee,  37232-6838
United States
 

NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York City,  New York,  10016
United States
 

Children's National Medical Center
Washington D.C.,  District of Columbia,  20010-2970
United States
 

Holden Comprehensive Cancer Center
Iowa City,  Iowa,  52242-1009
United States
 

Lineberger Comprehensive Cancer Center, UNC
Chapel Hill,  North Carolina,  27599-7295
United States
 

Fred Hutchinson Cancer Research Center
Seattle,  Washington,  98109-1024
United States
 

Children's Hospital of Orange County
Orange,  California,  92868
United States
 

David Grant Medical Center
Travis Air Force Base,  California,  94535
United States
 

Cancer Institute of New Jersey
New Brunswick,  New Jersey,  08903
United States
 

Ireland Cancer Center
Cleveland,  Ohio,  44106-5065
United States
 

Jonsson Comprehensive Cancer Center, UCLA
Los Angeles,  California,  90095-1781
United States
 

Children's Hospital and Regional Medical Center - Seattle
Seattle,  Washington,  98105
United States
 

Children's Hospital Medical Center - Cincinnati
Cincinnati,  Ohio,  45229-3039
United States
 

University of Minnesota Cancer Center
Minneapolis,  Minnesota,  55455
United States
 

University of Michigan Comprehensive Cancer Center
Ann Arbor,  Michigan,  48109-0752
United States
 

Princess Margaret Hospital for Children
Perth,  Western Australia,  6001
Australia
 

UCSF Cancer Center and Cancer Research Institute
San Francisco,  California,  94143-0128
United States
 

Children's Hospital of Philadelphia
Philadelphia,  Pennsylvania,  19104
United States
 


Additional Information:
Study ID Numbers:
  CDR0000067125;  CCG-B9805
Study Start Date: April 1999
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003933

Other Recurrent Childhood Acute Lymphoblastic Leukemia Studies:
1. STI571 in Treating Patients With Recurrent Leukemia

2. Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

3. Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

4. BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

5. Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia

Related Studies:

Other recurrent childhood acute lymphoblastic leukemia Clinical Trials
Other Tennessee Clinical Trials
Other Nashville Clinical Trials

Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia

Modify your Search

  Other recurrent childhood acute lymphoblastic leukemia Clinical Trials
  Other Tennessee Clinical Trials
  Other Nashville Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103